This is a summary of the European public assessment report (EPAR) for Refixia. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Refixia. For practical information about using Refixia, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). Refixia can be used for all age groups.
Therapeutic Area (MeSH)
N/AATC Code
B02BD04
ATC Item
coagulation factor IX
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| nonacog beta pegol | N/A | Nonacog beta pegol |
| Nonacog beta pegol | N/A | Nonacog beta pegol |
EMA Name
Refixia
Medicine Name
Refixia
Aliases
N/ANo risk management plan link.
